Medtronic in vascular puncture haemostasis deal with Scion
This article was originally published in Clinica
Executive Summary
Medtronic is to have exclusive distribution rights to Scion Cardio-Vascular's Clo-Sur PAD, used for the rapid control of bleeding from vascular access sites, and has made a minority equity in investment in the Miami, Florida-based company. Under the deal with Medtronic, use of the noninvasive device is limited to the control of bleeding following catheter removal associated with a catheterisation procedure, such as stenting, and other minimally invasive procedures.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.